Increased phosphorylation of ERK1/2 is associated with worse chemotherapeutic outcome and a poor prognosis in advanced lung adenocarcinoma

Biomarkers in Lung Adenocarcinoma: A Decade of Progress

(2015) Lynette M. Sholl   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non–Small-Cell Lung Cancer: A Mini-Review

(2015) Samuel J. Klempner et al.   Clinical Lung Cancer

Genomic alterations in lung adenocarcinoma

(2015) Siddhartha Devarakonda et al.   LANCET ONCOLOGY

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

(2015) William H. Chappell et al.   Oncotarget

Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer

(2014) Nobuaki Ochi et al.   EXPERIMENTAL CELL RESEARCH

The clinical development of MEK inhibitors

(2014) Yujie Zhao et al.   Nature Reviews Clinical Oncology

Prognostic and predictive biomarkers in lung cancer. A review

(2014) Erik Thunnissen et al.   VIRCHOWS ARCHIV

Utility of the Quantitative Ki-67 Proliferation Index and CD56 Together in the Cytologic Diagnosis of Small Cell Lung Carcinoma and Other Lung Neuroendocrine Tumors

(2013) Gang Zheng et al.   ACTA CYTOLOGICA

Semi-Nested Real-Time Reverse Transcription Polymerase Chain Reaction Methods for the Successful Quantitation of Cytokeratin mRNA Expression Levels for the Subtyping of Non-Small-Cell Lung Carcinoma Using Paraffin-Embedded and Microdissected Lung Biopsy Specimens

(2013) Yoko Nakanishi et al.   ACTA HISTOCHEMICA ET CYTOCHEMICA

Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies

(2013) D. M. Shin et al.   CLINICAL CANCER RESEARCH

Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer

(2013) S. Cardarella et al.   CLINICAL CANCER RESEARCH

Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non–Small-Cell Lung Cancer Segregated According to KRAS Mutation Status

(2013) Giulio Metro et al.   Clinical Lung Cancer

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

(2013) Neal I. Lindeman et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Genetics and biomarkers in personalisation of lung cancer treatment

(2013) Rafael Rosell et al.   LANCET

pERK 1/2 inhibit Caspase-8 induced apoptosis in cancer cells by phosphorylating it in a cell cycle specific manner

(2013) Ranadip Mandal et al.   Molecular Oncology

Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry

(2012) Gou Mizutani et al.   ACTA HISTOCHEMICA ET CYTOCHEMICA

Association ofKRASandEGFRmutations with survival in patients with advanced lung adenocarcinomas

(2012) Melissa L. Johnson et al.   CANCER

Impact of KRAS and EGFR Gene Mutations on Recurrence and Survival in Patients with Surgically Resected Lung Adenocarcinomas

(2011) Makoto Sonobe et al.   ANNALS OF SURGICAL ONCOLOGY

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA

(2011) Tomomi Nakamura et al.   Journal of Thoracic Oncology

New driver mutations in non-small-cell lung cancer

(2011) William Pao et al.   LANCET ONCOLOGY

Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases

(2011) M. Cargnello et al.   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation

(2011) Yuji Kubota et al.   NATURE CELL BIOLOGY

A Fully Integrated and Automated Detection System for Single Nucleotide Polymorphisms of UGT1A1 and CYP2C19

(2011) Norio Ureshino et al.   ONCOLOGY RESEARCH

Activation of FOXO3a Is Sufficient to Reverse Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor Chemoresistance in Human Cancer

(2010) Jer-Yen Yang et al.   CANCER RESEARCH

Utilization of cytokeratin-based biomarkers for pharmacodynamic studies

(2010) Stig Linder et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

(2010) John D. Hainsworth et al.   Journal of Thoracic Oncology

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activation of the MEK–S6 Pathway in High-grade Ovarian Cancers

(2010) Aviva P. Ventura et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

(2009) K. Takeuchi et al.   CLINICAL CANCER RESEARCH

MAPK signaling pathways in the regulation of hematopoiesis

(2009) Christian R. Geest et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts

(2008) K. Takeuchi et al.   CLINICAL CANCER RESEARCH